美国血管内与外科动静脉瘘建立的成本效益分析
研究构建决策树和概率队列状态转换模型,比较血管内动静脉瘘(endoAVF)与外科动静脉瘘(sAVF)的成本效益。
要点
- 在5年时间跨度内,endoAVF相比sAVF的增量成本效益比为每QALY 227504美元,超过50000美元的支付意愿阈值。
- 概率敏感性分析中sAVF在71%的迭代中仍为最优策略。
- 当sAVF初始成本超过endoAVF至少600美元、endoAVF成熟率>90%或sAVF成熟率<65%时,endoAVF才具有成本效益。
核心结论
- 在模拟5年结局时,endoAVF与sAVF相比不具备成本效益。
- sAVF保持成本效益的主要驱动因素是endoAVF建立的前期成本高出四倍,以及endoAVF带来的生活质量额外提升相对较低。
- 建立endoAVF学习曲线如何影响前期成本很重要,鉴于全国血管通路相关的年度成本,有必要开展随机对照试验。
研究设计与样本
- 研究构建决策树,随后采用概率队列状态转换模型,比较endoAVF与sAVF建立的成本效益。
- 通过系统综述获取技术成功率、成熟率、通畅率和效用值等输入参数。
- 成本来源于2022年Medicare收费表和文献。
- 采用5年时间跨度,成本和效用(以质量调整生命年QALY衡量)的年贴现率为3%,支付意愿阈值为50000美元。
- 进行了单因素和蒙特卡洛概率敏感性分析,变化技术成功率、通畅率、再干预、成本和效用参数。
主要发现
- 单因素敏感性分析中,当sAVF建立初始成本超过endoAVF至少600美元(例如endoAVF建立成本≤3000美元,而基础案例sAVF成本为3600美元)时,endoAVF具有成本效益。
- 单因素敏感性分析中,当endoAVF额外获得的QALY超过每年0.12个QALY(例如endoAVF每年获得0.81个QALY,而基础案例sAVF每年获得0.69个QALY)时,endoAVF具有成本效益。
- 单因素敏感性分析中,当endoAVF成熟率>90%(基础案例78%)或sAVF成熟率<65%(基础案例78%)时,endoAVF具有成本效益。
- 概率敏感性分析显示,sAVF在71%的迭代中仍为最优策略。
关键数值与推荐
- 支付意愿阈值为50000美元/QALY。
- 基础案例中endoAVF的增量成本效益比为每QALY 227504美元。
- 概率敏感性分析中sAVF在71%的迭代中为最优策略。
- 当sAVF初始成本超过endoAVF至少600美元时,endoAVF具有成本效益。
- 当endoAVF成熟率>90%或sAVF成熟率<65%时,endoAVF具有成本效益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the United States, an estimated $2.8 billion annually is spent on vascular access and its complications. Endovascular arteriovenous fistula (endoAVF) creation is a novel, minimally invasive alternative to traditional surgical AV fistula (sAVF) creation in ≤60% of patients. Although cost effective in single-payer systems, the clinical and financial impact of endoAVF in the United States remains uncertain. METHODS: We constructed a decision tree followed by a probabilistic cohort state-transition model to study the cost effectiveness of endoAVF vs sAVF creation. We conducted a systematic review to obtain input parameters including technical success, maturation, patency, and utility values. We derived costs from the Medicare 2022 fee schedule and from the literature. We used a 5-year time horizon, an annual discount rate of 3% for costs and utilities (measured in quality-adjusted life-years [QALYs]), and the common willingness-to-pay threshold of $50,000. One-way and Monte Carlo probabilistic sensitivity analyses were performed varying technical success, patency, reintervention, cost, and utility parameters. RESULTS: In the base-case scenario, endoAVF ($30,129 average per-person costs, 2.19 QALYs gained, 65% patent at 5 years) was not cost effective compared with sAVF ($12.987 average per-person costs, 2.11 QALYs gained, 66% patent at 5 years), generating an incremental cost-effectiveness ratio of $227,504 per QALY gained. In one-way sensitivity analyses, endoAVF becomes cost effective when the initial cost of sAVF creation exceeds endoAVF by ≥$600 (eg, if endoAVF creation costs ≤$3000 relative to the base-case sAVF cost of $3600), the additional QALYs gained from endoAVF exceeds 0.12 QALYs/year (eg, 0.81 QALYs gained/year from endoAVF compared with base-case sAVF 0.69 QALYs/year), the endoAVF maturation rate is >90% (base case 78%), or the sAVF maturation rate is <65% (base case 78%). Probabilistic sensitivity analysis demonstrated that sAVF remained the optimal strategy in 71% of iterations. CONCLUSIONS: EndoAVF is not cost effective compared with sAVF when modeling 5-year outcomes. The main driver of sAVF remaining cost effective is the four times higher up-front cost for endoAVF creation, as well as a relatively low additional increase in quality of life for endoAVF. It will be important to establish how the endoAVF learning curve contributes to upfront costs and, given the annual cost attributed to vascular access nationally, a randomized controlled trial is warranted.
引用
- Mulaney-Topkar B, Ho VT, Sgroi MD, et al. Cost-effectiveness analysis of endovascular vs surgical arteriovenous fistula creation in the United States. J Vasc Surg. 2023. PMID: 37952783. doi:10.1016/j.jvs.2023.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。